MKI67 and neoplasm: The antitumour efficacy of combined miR‐126‐3p and miR‐221‐3p modulation was supported by the decrease in the number of Ki‐67‐expressing proliferating cells in tumours generated from miR‐modulated cells compared with those generated from SCR‐treated cells and the increase in the necrotic area (Fig. S8A).